{"symbol":"REGN","fiscalQuarter":"Q4-2011","reportDate":"2012-02-13","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2011","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 12.31%","keyNumbers":[{"metric":"EPS","actual":"$-0.37","expected":"N/A","surprise":"+41.08%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing research and development efforts.","They expressed confidence in future product pipelines."],"summary":"Overall, management conveyed a sense of cautious optimism regarding future growth. They emphasized their commitment to innovation despite current challenges."},"guidanceChanges":{"summary":"No guidance data was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report shows a significant surprise in EPS, which contributed to a strong stock reaction, rising 12.31%. Investors may be encouraged by the positive EPS surprise, indicating better-than-expected performance despite the lack of revenue data. The management's focus on R&D suggests a commitment to future growth, which could further bolster investor confidence.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2011 earnings: EPS beat expectations. Stock up 12.31%. Full breakdown."}}